Stock Comparison
Pfizer Inc. vs Vertex Pharmaceuticals Incorporated
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Pfizer Inc.
PFE · New York Stock Exchange
Weighted across the company's segments.
Vertex Pharmaceuticals Incorporated
VRTX · The Nasdaq Global Select Market
Weighted across the company's segments.
Full stock profile
Dive deeper into Vertex Pharmaceuticals Incorporated's moat claims, evidence, and risks.
View VRTX analysisComparison highlights
- Moat score gap: Vertex Pharmaceuticals Incorporated leads (99 / 100 vs 58 / 100 for Pfizer Inc.).
- Segment focus: Pfizer Inc. has 5 segments (37.5% in Primary Care); Vertex Pharmaceuticals Incorporated has 4 segments (96.2% in Cystic Fibrosis CFTR Modulators).
- Primary market structure: Oligopoly vs Quasi-Monopoly. Pricing power: Moderate vs Strong.
- Moat breadth: Pfizer Inc. has 1 moat types across 1 domains; Vertex Pharmaceuticals Incorporated has 3 across 2.
Primary market context
Pfizer Inc.
Primary Care
Branded primary care medicines and vaccines (incl. cardiovascular, migraine, pneumococcal/RSV/COVID-19)
Global
Healthcare providers, payers/PBMs, pharmacies/wholesalers, and government procurement
Innovator biopharma (R&D + manufacturing + commercialization)
37.5%
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis CFTR Modulators
CFTR modulator therapies for cystic fibrosis
U.S., Europe, Australia, Canada
Patients (via specialty pharmacies/payers); CF care centers
Drug developer/manufacturer
96.2%
Side-by-side metrics
Moat coverage
Shared moat types
Pfizer Inc. strengths
No unique moat types yet.
Vertex Pharmaceuticals Incorporated strengths
Segment mix
Pfizer Inc. segments
Full profile >Primary Care
Oligopoly
Specialty Care
Oligopoly
Oncology
Competitive
Hospital and Biosimilars
Competitive
Pfizer CentreOne
Competitive
Vertex Pharmaceuticals Incorporated segments
Full profile >Cystic Fibrosis CFTR Modulators
Quasi-Monopoly
Hemoglobinopathies Gene Therapy (CASGEVY)
Oligopoly
Acute Pain (JOURNAVX)
Competitive
Rare endocrine diseases (PALSONIFY)
Competitive
Act on this comparison
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.